R&D Insight

Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin

This newsletter is part of a series — here are the links to Part 1, Part 3, and Part 4. Dear All (wonkish note alert!), The recent newsletter on chemicals, drugs, and halicin (link, see also a follow-up newsletter here) generated significant discussion and new insights that I thought I would share in a follow-up newsletter. Our

Read More »

Non-traditional antibiotics: A pipeline review and an analysis of key development challenges

Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress in a meaningful way (go here for Pew’s recent survey of the development landscape). Providing insights into the challenges of this area, two valuable and complementary articles on non-traditional antibiotics have recently

Read More »

AMR stays on the G20’s to-do list with calls for Push and Pull mechanisms

Aside: Please look closely at the forward calendar. In addition to two new webinars from GARDP’s REVIVE project, there is a meeting in Thailand in December that focuses on alternatives to antibiotics. I’m told that the program is primarily focused on veterinary and agricultural uses, but previous year’s attendees have found the discussion to have broad application

Read More »

Three $10k prizes for initiatives that improve access / create demand for diagnostics in LMICs

Dear All: Following the precept (often attributed to Osler, but I can’t find it in his Principles and Practice 1892) that the 3 core elements of treatment are “diagnosis, diagnosis, and diagnosis,” FIND (Foundation for Innovative New Diagnostics) is an international non-profit organization that enables the development and delivery of diagnostic tests for poverty-related diseases, including TB, malaria,

Read More »

UK Antibiotic Subscription Pilot: Post-webinar FAQ document

Dear All, Kevin Outterson and I recently shared our analysis of the NICE/NHS England pilot of an antibiotic procurement subscription model (link to that newsletter). The NICE/NHS team have now released a post-webinar FAQ document. Here is the link to the document … and I’ve also added the link to the initial webpage (cited just above) discussing

Read More »

Pull incentives for antibiotics: How much and why? — A literature survey

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter) and a new paper by Chantal Morel and colleagues on the idea of an Antibiotic Susceptibility Bonus (ASB, link) bring to the fore the question of how to value any given

Read More »

Let’s help Alan Carr do a COVID-19 point insight survey

Dear All, I promise that the next email will be all about the 25 Mar 2020 NHS England webinar on their antibiotic evaluation and procurement pilot (you’re going to love it … NICE and NHS England are doing great stuff … go here if you want to see a prior newsletter on this topic), BUT

Read More »
Scroll to Top